- Home
- NDLS vs CTOR Comparison
NDLS vs CTOR Comparison
Compare NDLS & CTOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NDLS
- CTOR
- Stock Information
- Founded
- NDLS 1995
- CTOR 2021
- Country
- NDLS United States
- CTOR United States
- Employees
- NDLS N/A
- CTOR N/A
- Industry
- NDLS Restaurants
- CTOR
- Sector
- NDLS Consumer Discretionary
- CTOR
- Exchange
- NDLS Nasdaq
- CTOR NYSE
- Market Cap
- NDLS 40.3M
- CTOR 48.1M
- IPO Year
- NDLS 2013
- CTOR N/A
- Fundamental
- Price
- NDLS $0.98
- CTOR $0.73
- Analyst Decision
- NDLS Strong Buy
- CTOR Strong Buy
- Analyst Count
- NDLS 2
- CTOR 2
- Target Price
- NDLS $3.00
- CTOR $4.50
- AVG Volume (30 Days)
- NDLS 84.8K
- CTOR 3.8M
- Earning Date
- NDLS 05-07-2025
- CTOR 05-21-2025
- Dividend Yield
- NDLS N/A
- CTOR N/A
- EPS Growth
- NDLS N/A
- CTOR N/A
- EPS
- NDLS N/A
- CTOR N/A
- Revenue
- NDLS $493,271,000.00
- CTOR N/A
- Revenue This Year
- NDLS $4.57
- CTOR N/A
- Revenue Next Year
- NDLS $1.29
- CTOR N/A
- P/E Ratio
- NDLS N/A
- CTOR N/A
- Revenue Growth
- NDLS N/A
- CTOR N/A
- 52 Week Low
- NDLS $0.55
- CTOR $0.55
- 52 Week High
- NDLS $2.36
- CTOR $49.00
- Technical
- Relative Strength Index (RSI)
- NDLS 46.30
- CTOR N/A
- Support Level
- NDLS $0.87
- CTOR N/A
- Resistance Level
- NDLS $0.96
- CTOR N/A
- Average True Range (ATR)
- NDLS 0.09
- CTOR 0.00
- MACD
- NDLS 0.01
- CTOR 0.00
- Stochastic Oscillator
- NDLS 59.78
- CTOR 0.00
About NDLS Noodles & Company
Noodles & Co is a restaurant concept offering lunch and dinner within the fast-casual segment of the restaurant industry. The company's menu includes a variety of cooked-to-order dishes, including noodles and pasta, soups, salads and appetizers. The company also provides dining, pick-up and delivery services.
About CTOR CITIUS ONCOLOGY INC
Citius Oncology Inc is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products targeting unmet needs with a focus on oncology products. In addition, Citius completed enrollment in its Phase 2b trial of CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids.